

21. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. *Am J Gastroenterol* 1996; 91: 423-33
22. Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. *Ann Pharmacother* 1996; 30: 951-4
23. Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. *Am J Gastroenterol* 2001; 96: 635-43
24. Targan S, Hanauer S, van Deventer S, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor- $\alpha$  for Crohn's disease. *N Engl J Med* 1997; 337: 1029-35
25. Feagan BG. Methotrexate treatment for Crohn's disease. *Inflamm Bowel Dis* 1998; 4: 120-1
26. Landewe RB, van den Borne BE, Breedveld FC, et al. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. *Lancet* 2000; 355: 1616-7
27. Tett SE, Triggs EJ. Use of methotrexate in older patients. A risk-benefit assessment. *Drugs Aging* 1996; 9: 458-71
28. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporin. *Am J Gastroenterol* 1998; 93: 442-8
29. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. *N Engl J Med* 1999; 340: 1398-405
30. Lichtenstein GR. Treatment of fistulizing Crohn's disease. *Gastroenterology* 2000; 119: 1132-47
31. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. *Gastroenterology* 1999; 117: 761-9
32. Camma C, Giunt M, Roselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: meta-analysis adjusted for confounding variables. *Gastroenterology* 1997; 113: 1465-73
33. Korelitz B, Hanauer S, Rutgeerts P, et al. Post-operative prophylaxis with 6MP, 5-ASA or placebo in Crohn's disease: a 2 year multicenter trial [abstract]. *Gastroenterology* 1998; 114: A1011
34. Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis. *Ann Intern Med* 1997; 126: 364-71
35. Spencer CM, McTavish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. *Drugs* 1995; 50: 854-72

---

Correspondence and offprints: Dr *Darrell S. Pardi*, 200 First Street SW, Rochester, Minnesota 55905, USA.  
E-mail: [pardi.darrell@mayo.edu](mailto:pardi.darrell@mayo.edu)

---

#### Erratum

**Vol. 19, No. 3, 2002, Page no 196:** In the legend of figure 4, it should read 'reproduced from Bloomfield et al.<sup>[8]</sup>, [Bloomfield DM. *Strategy for the Management of Vasovagal Syncope. Drugs & Aging* 2002; 19 (3): 179-202]

#### Addendum

**Vol. 18, No. 12, 2001, Page no 942:** After correspondence with the author of the original research article, the third sentence in the third bullet of the second column should read: 'The median duration of treatment was seven cycles, and the median dosage of tegafur/uracil was 330 mg/m<sup>2</sup>/day.'  
[Wellington K and Goa KL. *Oral Tegafur/Uracil. Drugs & Aging* 2001; 18 (12): 935-948]